Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Heparin acts as an anticoagulant and is used for conditions such as acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), cardiopulmonary bypass for heart surgery, Extracorporeal Membrane Oxygenation (ECMO) circuit for extracorporeal life support, hemofiltration, and indwelling central or peripheral venous catheters.
Europe heparin market is estimated to account for US$ 4,085.8 Mn in terms of value by the end of 2027.
Europe Heparin Market: Drivers
High prevalence of AF is expected to propel growth of Europe heparin market over the forecast period. For instance, according to Heart and Circulatory Disease Statistics 2019 Published by the British Heart Foundation (BHF) in collaboration with the Institute of Applied Health Research at the University of Birmingham, in April 2019, 185,423 men and 155,331 women were diagnosed with AF in England, Scotland, Wales, Northern Ireland and United Kingdom in 2017/18.
Moreover, R&D to expand the application of heparin is also expected to aid in growth of the market. For instance, in June 2020, researchers from Chungbuk National University, South Korea, reported that heparin-binding peptide has potential in treatment of rheumatic arthritis.
Germany held dominant position in Europe heparin market in 2019, accounting for 28.3% share in terms of volume, followed by France and U.K., respectively
Figure 1: Europe Heparin Market Share (%) Value, By Region, 2019
Europe Heparin Market: Restraints
Availability of alternative anticoagulants is expected to hinder growth of the market. Warfarin has traditionally been the key preferred drug for anticoagulant therapy globally. Moreover, the advent of new anticoagulants such as rivaroxaban, dabigatran, and apixaban is cannibalizing the market share of heparin.
Moreover, use of heparin may lead to elevation of serum aminotransferase levels, hyperkalemia, alopecia, and osteoporosis. Such side effects are also expected to limit growth of the market.
Europe Heparin Market Report Coverage
||Market Size in 2019:
||US$ 2,698.7 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 4,085.8 Mn
- Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe.
- By Product Type: Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin.
- By End User: Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers).
Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories
- Increasing prevalence of venous thromboembolism
|Restraints & Challenges:
- Risk of heparin induced thrombocytopenia
Europe Heparin Market: Opportunities
Use of sharp-catching label to prevent needlestick injuries is expected to offer lucrative growth opportunities for players in Europe heparin market. For instance, Heparin Sodium Injection USP prefilled syringes from B. Braun Medical Inc. have a needle-securing label, developed by Schreiner MediPharm, on medical packaging.
Moreover, R&D in the mechanism of heparin is also expected to aid in growth of the market. For instance, in May 2020, researchers from Martin Luther University Halle Wittenberg, Germany, reported examining the anti-inflammatory properties of surface coatings made of either hyaluronic acid or heparin in combination with chitosan prepared as multilayers through the layer-by-layer technique.
Europe heparin market was valued at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027.
Figure 2: Europe Heparin Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Major players in the market witnessed significant sales growth. For instance, in first quarter of 2020, Laboratorios Farmaceuticos Rovi S A reported increase in sales of the heparin franchise (LMWH and other heparins) by 42% to around US$ 60 million.
Major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment of VTE. For instance, in December 2019, the Bristol-Myers Squibb-Pfizer alliance announced that Eliquis use was associated with lower rates of major bleeding, clinically-relevant non-major bleeding and recurrent VTE compared to LMWH for the treatment of VTE in patients with active cancer, at the American Society of Hematology Annual Meeting.
Global Europe Heparin Market: Competitive Landscape
Major players operating in Europe heparin market include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Global Europe Heparin Market: Key Developments
Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in April 2018, Laboratorios Farmaceúticos Rovi SA signed a license expanding agreement with Hikma Pharmaceuticals PLC for ROVI’s enoxaparin biosimilar.